Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.

Funkhouser WK Jr, Hayes DN, Moore DT, Funkhouser WK 3rd, Fine JP, Jo H, Nikolaishvilli-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, Graziano P, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Hariri L, Driver B, Cagle PT.

Arch Pathol Lab Med. 2018 Apr 30. doi: 10.5858/arpa.2017-0481-OA. [Epub ahead of print]

PMID:
29708428
2.

Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.

Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA.

Arch Pathol Lab Med. 2018 Feb 12. doi: 10.5858/arpa.2017-0516-OA. [Epub ahead of print]

PMID:
29431467
3.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
4.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

PMID:
29396253
5.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22.

PMID:
29355391
6.

In Reply.

Nakhleh RE, Fitzgibbons PL, Washington MK, Baker TP, Berman MA, Cagle PT.

Arch Pathol Lab Med. 2018 Feb;142(2):161. doi: 10.5858/arpa.2017-0443-LE. Epub 2017 Nov 22. No abstract available.

PMID:
29166144
7.

Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.

Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT.

Arch Pathol Lab Med. 2017 Nov;141(11):1529-1532. doi: 10.5858/arpa.2017-0028-OA. Epub 2017 Aug 22.

PMID:
28829153
8.

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.

Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):408-419. doi: 10.5858/arpa.2017-0106-SA. Epub 2017 Jul 7.

PMID:
28686497
9.

Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Jain D, Allen TC, Aisner DL, Beasley MB, Cagle PT, Capelozzi VL, Hariri LP, Lantuejoul S, Miller R, Mino-Kenudson M, Monaco SE, Moreira A, Raparia K, Rekhtman N, Roden AC, Roy-Chowdhuri S, da Cunha Santos G, Thunnissen E, Troncone G, Vivero M.

Arch Pathol Lab Med. 2018 Feb;142(2):253-262. doi: 10.5858/arpa.2017-0114-SA. Epub 2017 Jun 22.

PMID:
28639854
10.

Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society.

Miller R, Allen TC, Barrios RJ, Beasley MB, Burke L, Cagle PT, Capelozzi VL, Ge Y, Hariri LP, Kerr KM, Khoor A, Larsen BT, Mark EJ, Matsubara O, Mehrad M, Mino-Kenudson M, Raparia K, Roden AC, Russell P, Schneider F, Sholl LM, Smith ML.

Arch Pathol Lab Med. 2018 Jan;142(1):120-126. doi: 10.5858/arpa.2017-0138-SA. Epub 2017 Jun 14. Review.

PMID:
28613913
11.

Molecular and Immune Biomarkers in Acute Respiratory Distress Syndrome: A Perspective From Members of the Pulmonary Pathology Society.

Capelozzi VL, Allen TC, Beasley MB, Cagle PT, Guinee D, Hariri LP, Husain AN, Jain D, Lantuejoul S, Larsen BT, Miller R, Mino-Kenudson M, Mehrad M, Raparia K, Roden A, Schneider F, Sholl LM, Smith ML.

Arch Pathol Lab Med. 2017 Dec;141(12):1719-1727. doi: 10.5858/arpa.2017-0115-SA. Epub 2017 Jun 14. Review.

PMID:
28613912
12.

The Future of College of American Pathologists Cancer Protocols: Maintaining a Commitment to Patient Safety While Improving the User Experience.

Nakhleh RE, Fitzgibbons PL, Washington MK, Baker TP, Berman MA, Cagle PT.

Arch Pathol Lab Med. 2017 Sep;141(9):1153-1154. doi: 10.5858/arpa.2017-0161-ED. Epub 2017 May 3. No abstract available.

PMID:
28467212
13.

Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.

Bernicker EH, Miller RA, Cagle PT.

J Oncol Pract. 2017 Apr;13(4):221-227. doi: 10.1200/JOP.2016.019182. Review.

PMID:
28399384
14.

#InSituPathologists: how the #USCAP2015 meeting went viral on Twitter and founded the social media movement for the United States and Canadian Academy of Pathology.

Cohen D, Allen TC, Balci S, Cagle PT, Teruya-Feldstein J, Fine SW, Gondim DD, Hunt JL, Jacob J, Jewett K, Jiang X', Kaplan KJ, Kulac I, Meunier R, Riddle ND, Rush PS, Stall J, Stuart LN, Terrano D, Uthman E, Wasco MJ, Williamson SR, Wu RI, Gardner JM.

Mod Pathol. 2017 Feb;30(2):160-168. doi: 10.1038/modpathol.2016.223. Epub 2017 Jan 13.

15.

Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society.

Roden AC, Aisner DL, Allen TC, Aubry MC, Barrios RJ, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Ge Y, Hariri LP, Lantuejoul S, Miller RA, Mino-Kenudson M, Moreira AL, Raparia K, Rekhtman N, Sholl L, Smith ML, Tsao MS, Vivero M, Yatabe Y, Yi ES.

Arch Pathol Lab Med. 2017 Mar;141(3):437-444. doi: 10.5858/arpa.2016-0459-SA. Epub 2016 Nov 7.

PMID:
27819763
16.

Management of the Solitary Pulmonary Nodule.

Chan EY, Gaur P, Ge Y, Kopas L, Santacruz JF, Gupta N, Munden RF, Cagle PT, Kim MP.

Arch Pathol Lab Med. 2017 Jul;141(7):927-931. doi: 10.5858/arpa.2016-0307-RA. Epub 2016 Sep 2. Review.

PMID:
27588335
17.

First-Line Immune Therapy-Implications for Pathologists.

Miller RA, Cagle PT, Bernicker EH.

Arch Pathol Lab Med. 2016 Aug;140(8):739-40. doi: 10.5858/arpa.2016-0904-ED. No abstract available.

PMID:
27472228
18.

Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society.

Raparia K, Aisner DL, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Rekhtman N, Roden AC, Roy-Chowdhuri S, Sholl L, Smith ML, Thunnissen E, Tsao MS, Yatabe Y.

Arch Pathol Lab Med. 2016 Jul 21. [Epub ahead of print]

PMID:
27441784
19.

PD-1/PD-L1, Only a Piece of the Puzzle.

Miller RA, Miller TN, Cagle PT.

Arch Pathol Lab Med. 2016 Jul 11. [Epub ahead of print] No abstract available.

PMID:
27399213
20.

Naissance of the Archives of Pathology & Laboratory Medicine: A Critical Analysis of the January 1926, Volume 1 Issue.

Gal AA, Cagle PT.

Arch Pathol Lab Med. 2016 Oct;140(10):1132-9. doi: 10.5858/arpa.2016-0250-SA. Epub 2016 Jul 11. No abstract available.

PMID:
27399212
21.

Forging into the Future: Archives Continues to Grow.

Cagle PT.

Arch Pathol Lab Med. 2016 Jun;140(6):500. doi: 10.5858/arpa.2016-0902-ED. No abstract available.

PMID:
27232342
22.

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao M, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2016 Aug;140(8):825-9. doi: 10.5858/arpa.2016-0163-SA. Epub 2016 May 19.

PMID:
27195432
23.

Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society.

Roy-Chowdhuri S, Aisner DL, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, da Cunha Santos G, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Moreira A, Raparia K, Rekhtman N, Sholl L, Thunnissen E, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]

PMID:
27081878
24.

Impact of Recent Developments in Lung Cancer on the Practice of Pathology.

Cagle PT, Allen TC, Bernicker EH, Ge Y, Haque A, Barrios R.

Arch Pathol Lab Med. 2016 Apr;140(4):322-5. doi: 10.5858/arpa.2015-0535-SA. Review.

PMID:
27028391
25.

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y; Members of Pulmonary Pathology Society.

Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18.

PMID:
26780537
26.

Emerging Biomarkers in Personalized Therapy of Lung Cancer.

Cagle PT, Raparia K, Portier BP.

Adv Exp Med Biol. 2016;890:25-36. doi: 10.1007/978-3-319-24932-2_2. Review.

PMID:
26703797
27.

Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.

Cagle PT, Bernicker EH.

Arch Pathol Lab Med. 2015 Dec;139(12):1477-8. doi: 10.5858/arpa.2015-0902-ED. No abstract available.

PMID:
26619015
28.

Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma.

Driver BR, Barrios R, Ge Y, Haque A, Tacha D, Cagle PT.

Arch Pathol Lab Med. 2016 Jul;140(7):682-5. doi: 10.5858/arpa.2015-0431-OA. Epub 2015 Nov 24.

PMID:
26599808
29.

Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.

Liu C, Pepper K, Hendrickson H, Cagle PT, Portier BP.

Arch Pathol Lab Med. 2016 Jul;140(7):690-3. doi: 10.5858/arpa.2015-0419-OA. Epub 2015 Nov 24.

PMID:
26599807
30.

A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.

Cagle PT, Bernicker EH.

Arch Pathol Lab Med. 2015 Nov;139(11):1329. doi: 10.5858/arpa.2015-0901-ED. No abstract available.

PMID:
26516934
31.

Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.

Driver BR, Portier BP, Mody DR, Deavers M, Bernicker EH, Kim MP, Teh BS, Santacruz JF, Kopas L, Munden RF, Cagle PT.

Arch Pathol Lab Med. 2016 Apr;140(4):312-7. doi: 10.5858/arpa.2015-0361-OA. Epub 2015 Oct 2.

PMID:
26430808
32.

Cancer biomarker testing in the everyday practice of pathology.

Cagle PT, Stein K, Oommen J, Shemon M, Kyle W.

Arch Pathol Lab Med. 2015 May;139(5):583-4. doi: 10.5858/arpa.2015-0025-ED. No abstract available.

PMID:
25927145
33.

A new ever-evolving paradigm.

Cagle PT, Olsen RJ, Portier BP, Takei H, Bernard DW.

Arch Pathol Lab Med. 2015 Apr;139(4):446-7. doi: 10.5858/arpa.2014-0629-ED. No abstract available.

PMID:
25822762
34.

The 2015 Physician Quality Reporting System reflects pathologists' role in lung cancer biomarker testing.

Cagle PT, Allen TC.

Arch Pathol Lab Med. 2015 Apr;139(4):445. doi: 10.5858/arpa.2014-0619-ED. Epub 2015 Feb 2. No abstract available.

PMID:
25643045
35.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.

Brat DJ, Cagle PT, Dillon DA, Hattab EM, McLendon RE, Miller MA, Buckner JC; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2015 Sep;139(9):1087-93. doi: 10.5858/arpa.2014-0588-CP. Epub 2015 Feb 2. No abstract available.

PMID:
25642959
36.

Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.

Zhang K, Deng H, Cagle PT.

Arch Pathol Lab Med. 2014 Dec;138(12):1611-28. doi: 10.5858/arpa.2014-0092-RA. Review.

PMID:
25427041
37.

Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation.

Litvinov J, Hagström AE, Lopez Y, Adhikari M, Kourentzi K, Strych U, Monzon FA, Foster W, Cagle PT, Willson RC.

Biotechnol Lett. 2014 Sep;36(9):1863-8. doi: 10.1007/s10529-014-1555-9. Epub 2014 Jun 15.

38.

Whole slide images add value to journal article figures.

Cagle PT, Glassy EF.

Arch Pathol Lab Med. 2014 May;138(5):592. doi: 10.5858/arpa.2014-0042-ED. No abstract available.

PMID:
24786116
39.

Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.

Raparia K, Villa C, Raj R, Cagle PT.

Arch Pathol Lab Med. 2015 Feb;139(2):189-93. doi: 10.5858/arpa.2013-0759-OA. Epub 2014 Apr 2.

PMID:
24694341
40.

Well-differentiated papillary mesothelioma with invasive foci.

Churg A, Allen T, Borczuk AC, Cagle PT, Galateau-Sallé F, Hwang H, Murer B, Murty VV, Ordonez N, Tazelaar HD, Wick M.

Am J Surg Pathol. 2014 Jul;38(7):990-8. doi: 10.1097/PAS.0000000000000200.

PMID:
24618613
41.

Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.

Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, DeCamp MM, Raparia K.

Arch Pathol Lab Med. 2014 Oct;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA. Epub 2014 Feb 26.

PMID:
24571650
42.

The presence of anti-HLA donor-specific antibodies in lung allograft recipients does not correlate with C4d immunofluorescence in transbronchial biopsy specimens.

Roberts JA, Barrios R, Cagle PT, Ge Y, Takei H, Haque AK, Burns KM, Land GA, Dilioglou S, Bernard DW.

Arch Pathol Lab Med. 2014 Aug;138(8):1053-8. doi: 10.5858/arpa.2013-0539-OA. Epub 2013 Oct 28.

PMID:
24164556
43.

Lung cancer biomarkers: present status and future developments.

Cagle PT, Allen TC, Olsen RJ.

Arch Pathol Lab Med. 2013 Sep;137(9):1191-8. doi: 10.5858/arpa.2013-0319-CR. Review.

PMID:
23991729
44.

EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma.

Zhang W, McQuitty EB, Olsen R, Fan H, Hendrickson H, Tio FO, Newton K, Cagle PT, Jagirdar J.

Arch Pathol Lab Med. 2014 Apr;138(4):543-5. doi: 10.5858/arpa.2013-0311-OA. Epub 2013 Aug 12.

PMID:
23937608
45.

Pulmonary sclerosing papillary adenoma.

Allen TC, Amrikachi M, Cagle PT.

Pathol Int. 2013 Jul;63(7):364-7. doi: 10.1111/pin.12075.

PMID:
23865575
46.

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.

Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris DX, Foulis P, Lee G, Neal JW, Nowak JA, Yu PP; Members of the Cancer Biomarker Reporting Workgroup, College of American Pathologists.

Arch Pathol Lab Med. 2014 Feb;138(2):171-4. doi: 10.5858/arpa.2013-0232-CP. Epub 2013 Jun 28. No abstract available.

PMID:
23808401
47.

Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients.

McQuitty E, Zhang W, Hendrickson H, Tio FO, Jagirdar J, Olsen R, Cagle PT.

Arch Pathol Lab Med. 2014 Mar;138(3):390-4. doi: 10.5858/arpa.2013-0225-OA. Epub 2013 Jun 26.

PMID:
23802852
48.

p16 Deletion in sarcomatoid tumors of the lung and pleura.

Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle PT, Dacic S.

Arch Pathol Lab Med. 2013 May;137(5):632-6. doi: 10.5858/arpa.2012-0108-OA.

PMID:
23627453
49.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M, College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology.

J Mol Diagn. 2013 Jul;15(4):415-53. doi: 10.1016/j.jmoldx.2013.03.001. Epub 2013 Apr 4. Erratum in: J Mol Diagn. 2013 Sep;15(5):730.

50.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.

J Thorac Oncol. 2013 Jul;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f. Erratum in: J Thorac Oncol. 2013 Oct;8(10):1343.

Supplemental Content

Loading ...
Support Center